Introduction

FDAH

Address: Flanders Road

Hedge End

Southampton SO30 4QH

Telephone: 01489 781711

Fax: 01489 788306

Presentation

A milky white suspension for injection containing inactivated, adjuvanted feline leukaemia virus, subgroups A and B, 1.0 RP* per 1 ml dose.

*RP = Relative Potency unit of FeLV antigen gp70

Uses

For the primary and booster vaccination of healthy, susceptible, unexposed, immune competent cats and kittens against feline leukaemia.

Dosage and administration

Shake well before use. Administer the contents of one vial (1 ml) by subcutaneous injection using aseptic technique.

Primary vaccination: A primary vaccination course consists of 2 doses, three to four weeks apart. The primary vaccination of kittens should start from the age of 9 weeks.

The vaccination of female cats prior to mating is recommended to provide maternally derived antibody for the kittens.

Boosting vaccination: A single annual booster vaccination is recommended for the maintenance of protection.

Contra-indications, warnings, etc

Do not vaccinate sick cats.

Do not vaccinate pregnant queens.

Avoid stress around the time of vaccination.

Local injection site reactions such as swelling, pain, pruritis or hair loss may occur post vaccination. A small percentage of vaccinated cats may also develop post vaccination reactions such as fever, vomiting, anorexia and lethargy.

Hypersensitivity reactions such as urticaria or facial oedema, sometimes accompanied by respiratory signs have been reported.

In the event of an allergic reaction, immediate treatment should be given using epinephrine (adrenaline) intramuscularly and/or a short acting glucocorticoid (eg dexamethasone sodium phosphate) intravenously.

Animals that have received immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.

No information is available on the safety and efficacy from the concurrent use of this vaccine with any other product except Katavac CHP or Eclipse IV provided that these two vaccines are authorised. It is therefore recommended that no other vaccines than these should be administered within 14 days before or after vaccination with the product.

Vaccination has no known beneficial effect in cats already infected with FeLV. Therefore, diagnostic testing of cats for the presence of feline leukaemia (FeLV) core protein p27 in serum prior to vaccination may be advisable.

In any population there will be a small number of individuals that shows no or only a slight immunological response to the vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the animal's ability to respond. The immunological response may be influenced by hereditary factors, intercurrent infection, subclinical infection, age, nutritional status, concurrent drug therapy, stress, etc.

Pharmaceutical precautions

Store and transport refrigerated (+2°C to +8°C). Protect from light.

Use aseptic technique.

Syringes and needles should not have been sterilised chemically or be above ambient temperature. Do not use chemicals to disinfect or sterilise the skin.

Do not freeze. Keep out of the reach of children.

For animal treatment only.

Legal category

POM-V

Packaging Quantities

10 x 1 dose.

Further information

As Fevaxyn FeLV is a whole virus vaccine it presents a number of potentially antigenic proteins, in combination with an aqueous adjuvant. The antigen was selected on its immunogenic property. The FeLV subgroup-A Rickard strain is known to cause the typical symptoms of Feline Leukaemia. Subgroup-B and subgroup-C are recombinations of subgroup-A with cat genome sequences. Subgroup-A and B are part of Fevaxyn FeLV vaccine antigen and should also immunise against subgroup-C.

Fevaxyn FeLV is fully compatible with Katavac CHP so all antigens can be administered by one injection.